DPP4 and hepatocellular carcinoma: More recently, a large Scandinavian cohort comparing GLP‐1 RAs with DPP‐4 inhibitors reported a lower risk of serious liver events (adjusted HR 0.85 [0.75–0.97]), driven by reduced cirrhosis, with no clear effect on hepatocellular carcinoma (HR 1.05 [0.80–1.39]) [30].